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Who cares wins? A comparative analysis of household waste medicines and 
batteries reverse logistics systems – the case of the NHS (UK). 
 
Abstract 
Purpose  
The purpose of this paper is to determine how best to reduce, reuse and dispose of household 
waste medicines in the National Health Service (NHS) (UK).  
 
Design/Methodology/Approach 
Through a combination of literature review and empirical work, this research investigates the 
existing household waste medicines Reverse Logistics (RL) system, and makes 
recommendations for improvement by benchmarking it against household waste batteries RL 
system. The viability and feasibility of these recommendations are evaluated through in-depth 
interviews with healthcare professionals and end user surveys.  
 
Findings 
The batteries RL system appears to be a more structured and effective system with more 
active engagement from actors/stakeholders in instigating RL practices and for this very 
reason is an excellent comparator for waste medicines RL practices.  Appropriate best 
practices are recommended to be incorporated into the waste medicines RL system, including 
recapturing product value, revised processing approaches, system co-operation and 
enforcement, drivers and motivations, and system design and facilitation.   
 
Research implications/limitations 
This study offers academics and professionals an improved insight into the current household 
waste medicines RL system, and provides a step towards reducing an existing gap in this 
under-researched area. A limitation is that only a small sample of healthcare professionals 
were involved in subjectively evaluating the feasibility of the recommendations, so the 
applicability of the recommendations needs to be tested in a wider context and the cost 
effectiveness of implementing the recommendations needs to be analysed.  
  
Practical implications 
Reducing, reusing and properly disposing of waste medicines contribute to economic 
sustainability, environmental protection and personal and community safety. The information 
retrieved from analysing returned medicines can be used to inform prescribing practice so as 
to reduce unnecessary medicine waste and meet the medicine optimisation agenda.   
 
Originality/value 
This paper advocates learning from best practices in batteries RL to improve the waste 
medicines RL design and execution, and it supports the current NHS agenda on medicine 
waste reduction (DoH, 2012). The recommendations made in the paper not only aim to 
reduce medicine waste, but also to use medicines effectively, placing the emphasis on 
improving health outcomes.  
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Paper type 
Research 
 
1 Introduction 
Research commissioned by the Department of Health (DoH) has found that NHS England 
prescription medicine waste cost £300 million a year in 2009, and about £90 million worth of 
medicines are stored in people’s homes at any one time (DoH, 2011). The Department for 
Environment, Food & Rural Affairs (DEFRA) in the UK regulates that medicine waste 
produced at home is separated from mainstream household waste, and the recommended 
means of disposal is to return them to pharmacies.  In this research, we refer to medicine 
waste residing within homes as household waste medicines. Such waste not only causes 
economic loss, but also has an adverse impact on the environment and on human health if the 
waste is ineffectively disposed of (Daughton and Ternes 1999). Safety is also paramount if 
medicines fall into the hands of children or individuals who wish to abuse the medicines 
themselves or support a ‘grey’ market for medicines exchange/sale for cash. Medicine waste 
is the result of a number of factors, encompassing: i) patients recovering before their 
dispensed medicines have all been taken; ii) therapies being stopped or changed because of 
ineffectiveness and/or unwanted side effects; iii) patients’ deaths; and iv) factors relating to 
repeat prescribing and dispensing processes (DoH, 2011).  
 
To protect the environment, reduce economic loss and increase the safety of medicine use, 
the DoH produced a series of guidance information on managing waste medicines, stating 
that community pharmacies are bound by contractual obligation to offer a return service for 
medication (DoH, 2011). However, the predominant method of disposal of household waste 
medicines in the UK is via household waste, and the disposal habit becomes an obstacle to 
developing effective healthcare waste management practice/systems in community 
Pharmaceutical Supply Chains (PSC) (Bound and Voulvoulis, 2005). The national public 
survey conducted in 2009 (DoH, 2011) found that the return rate to pharmacies is 40%, 
attributed to the fact that the sample included relatively high numbers of individuals with an 
above average interest in the subject and who might be comparatively careful medicines users.  
 
In December 2012, the NHS (UK) launched an action plan to reduce medicine waste. The 
plan aimed to determine how best practice can be shared to improve the use of medicines and 
address medicine wastage within the NHS (DoH, 2012). Whilst this study was not involved 
in this analysis, it runs parallel to it and has the same aim: to determine how best to reduce 
waste medicines in the NHS (UK). The contracts governing the collection and disposal of 
waste medicines are organised regionally by Clinical Commissioning Groups (CCGs), a 
consortium of General Practitioner (GP
1
) groups. Prior to April 2013 these were known as 
Primary Care Trusts (PCT) and there will be reference to PCTs in the findings of this study as 
data was sourced from PCT professionals.    
 
On a commercial level, medication is a product, and it enters the Reverse Logistics (RL) 
channel once it is retrieved from the end users. The focus of the research was on medicines 
prescribed by a doctor or other healthcare professionals rather than medicines bought over the 
counter, therefore end users are used to replace customers and refer to patients in a PSC. The 
RL system facilitates material reduction, reuse of products, refurbishment, repair, 
                                                          
1
 GP is a medical practitioner who treats, and provides preventive care and health education to patients. 
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remanufacturing, recycling of materials, and waste disposal (Stock, 1998; Van Hoek, 1999). 
Medication retrieved from end users cannot be reused and must be denatured and disposed of, 
although there are proposals to reuse expensive medication (Pomerantz, 2004) or to donate 
some medicines (InterCare, 2012). As there is no commercial value left in the medicines 
returned, RL of waste medicines gains very little attention (Xie and Breen, 2012; Ritchie et 
al., 2000), in comparison with research in other sectors where RL aims to recapture value 
from returned products and direct them towards a second market. The first research objective 
hence originates at this point; to investigate the existing RL system for household waste 
medicines in NHS community pharmacies. Although returned medicines are regarded as 
waste, they are also special types of End-of Life (EoL) or End-of-Use (EoU) returns of 
consumer goods, and initially source reduction strategies should be considered and developed 
to minimise waste production (Marien, 1998). The EoL returns are defined as “the returns 
taken back from the market to avoid environmental or commercial damage” Krikke et al. 
(2004, pp.26), and they are either returned to the original equipment manufacturer because of 
legal take back obligations, or other companies for value-added recovery, or environmental 
agencies for landfill or incineration. InterCare redistribute returned medicines to 
underdeveloped countries for free, and these medicines are regarded as EoU returns, i.e., 
products “returned after some period of operations due to the end of leasing, trade-in or 
product replacement” but still preserving functionality intact and capable of being reused 
(Krikke et al., 2004, pp.26). Greater contributions can be made if an effective and well-
designed RL system is in place to reduce avoidable waste medicines (Xie and Breen, 2012), 
and reuse EoU medicines (InterCare, 2012), and properly dispose of EoL medicines, thereby 
reducing impacts on the environment and the risk of accidental injury or planned product 
abuse. 
 
Previous research on RL has focused on improving business performance in various non-
pharmaceutical industrial sectors, for example, household batteries (Kannan 2009, Zhou et al., 
2007, Bartels, 1998).  There are similarities between these two RL systems; for example, both 
waste medicines and batteries contain hazardous components and need separate collection 
and reprocessing. However, the lifecycles of some battery components are extended by 
reusing or recycling; whereas the majority of waste medicines are disposed of, and only a 
very limited portion of returned medicines are reused if they are intact, in good condition and 
in date. The RL system for household waste batteries is studied as the second research 
objective and, based on examination of its content and application, it appears to be more 
structured and effective in engaging actors and achieving customer buy-in and uptake.  
Therefore, the third research objective is to compare the operational practices within these 
two industries, and recommending best practices.  
 
In summary there are 3 research objectives for this study which will be addressed and 
delivered to in the following discussion: 
 
I. To study the current RL system for household waste medicines 
II. To study the existing RL system for household waste batteries 
III. To compare both systems above, identify gaps and best operational practices and 
deliver grounded recommendations for future design and practice.  
 
The remainder of this paper is organised as follows: a literature review on RL is presented in 
Section 2, followed by theoretical underpinning and propositions in Section 3. The research 
methodologies are justified in Section 4. In Section 5, the existing RL systems are identified 
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for household waste medicine and batteries, respectively. A benchmarking process is applied. 
Discussions and managerial implications of the findings are presented in Section 6. Finally, 
conclusions and future work are presented in Section 7.  
 
2 Literature review 
The literature on RL is broad and diverse, but there is little research that focuses on 
developing theory for RL. Literature in related fields secondarily adds to the theoretical 
growth of RL, and have been summarised and classified by Dowlatshahi (2000) in five 
categories: i) basic concepts and a summary of RL; ii) quantitative models on RL; iii) 
research dealing with more specific logistical issues; iv) the critical roles of manufacturing 
technologies and their impacts on RL performances; and v) the applications of RL in different 
industrial sectors. In addition, the recent literature investigated: vi) the capability, 
effectiveness and performance of a RL system; (vii) the motivators and the barriers of a RL 
system; and (viii) how information technology influences and facilitates the operation of a 
RL system. De Brito and Dekker (2004) developed a framework for understanding RL under 
four dimensions (see Table 1): “What”, “How”, “Who” and “Why and Why not”, and 
illustrated that the issues arising from RL system can be orchestrated by the four dimensions. 
To obtain theoretically grounded and holistic views on RL, this framework is adapted in the 
research and named as the RL framework, by adding another dimension “Where” (see Table 
1) to address specific RL issues such as locations of collection points in a physical RL 
network.  
Insert Table 1 here. 
 
 As shown in Table 2, the literature can be placed within the context of the RL framework, 
addressing one or more dimensions.  
 
Insert Table 2 here. 
 
Although industries have various levels of involvement with RL, applications of RL practices 
are regarded as difficult, as they complicate the traditional forward SC (Li and Olorunniwo, 
2008). RL for waste medicines is more challenging and difficult to implement for the 
following reasons: a) Lack of motivation: There is less commercial motivation for actors in 
PSC to return or collect waste medicines, nor has the legislation been enacted requiring actors 
to do so. b) Challenge of change:  Revising and improving the existing household waste 
medicines RL system will inevitably incur cost to NHS CCGs.  However, reducing and 
managing medicine waste is a more cost effective way to increase the overall health and 
wellbeing of heath service users by directly and effectively contributing to improving care 
quality and health outcomes (DoH, 2010).  
 
Research on RL in pharmaceutical industries has been conducted for B2B returns from 
entities within the PSC (Kumar et al., 2009), or for by-products within the manufacturing 
plant (Teunter et al., 2005). This research focuses on the household waste medicines returned 
by end users.  
 
3 Theoretical underpinning and propositions 
There are no established references on designing an RL system and the integral practices 
within it, so we use related literature to underpin practices proposed for a generic household 
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waste system (Table 3) and then as applied to both batteries and waste medicines RL systems 
(Table 6). Dowlatshahi (2000) described a holistic view of RL by developing 11 factors for 
successful design and implementation of RL. The strategic factors consist of strategic costs, 
overall quality, customer service, environmental concerns, and legislative concerns. The 
operational factors consist of cost-benefit analysis, transportation, warehousing, supply 
management, remanufacturing and recycling, and packaging. These factors are framed as 
testable propositions for a household waste RL, and we use the RL framework (see Table 1) 
to discuss and complement the propositions (see Table 3).  
 
Insert Table 3 here 
    
3.1 Propositions under the RL framework 
We propose that products with residual value are more likely to enter the reverse flows of a 
RL system, where returned products are reprocessed to recover value. Household waste 
counted as EoU returns can be directly reused or resold, while there is an order of favourable 
resource recovery options for those counted as EoL returns: reuse, remanufacturing, parts 
retrieval and material recycling. Actors in a RL system are made more active and engaged in 
RL activities due to legislation, economic drivers, corporate social responsibility and 
environmental concerns. Engagement can also be stimulated if the convenience of 
returning/collection is improved.  However, the success of a RL requires total involvement 
and effort from every actor in the RL system.  
 
What 
The aspect “what” considers what is actually being discarded or returned, and four intrinsic 
product characteristics are discussed here as they are influential on the RL activities: 
composition, deterioration (De Brito and Dekker, 2004), dimensional size (Goggin and 
Browne, 2000) and packaging solution (Silvenius et al., 2013).  
 
Product composition in terms of components, of materials and the number of components, 
affects the ease of returning/collecting, and reprocessing them and, the associated values 
recovered from them (Goggin and Browne, 2000).  
 
A further characteristic is deterioration, which determines whether there is enough 
functionality left within a product to make further use or recapture of residual value from its 
parts/components viable. In addition, residual value depends on other factors: legislation that 
regulates the usability of the returned product; the existence of a secondary market (Gobbi, 
2011) and the cost of the recovery process (Stock and Mulki, 2009). This deterioration 
characteristic strongly affects the recovery option, as well as actors’ engagement in RL 
activities. Products may become obsolete because of replacement by a new product, ageing 
and expiry, or a product may become “obsolete” because of legislation restricting reuse of the 
returned products, as is the case with medicines. In both cases, reuse or resale of product is 
not an option; instead, parts retrieval can be considered if some components or packaging 
have not deteriorated. The findings from Gobbi (2011) indicate that knowing the residual 
value of the returned product can enhance actors’ engagement in the recycling processes.  
 
The dimensional size of the product is also an important factor affecting RL activities 
(Goggin and Browne, 2000). Small products tend to be discarded or stored rather than 
returned, while big products are more challenging to be transported and handled if returned.  
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Package solution of a product can have an influence on a RL that is required to process 
package related waste, and it concerns package sizes, shapes, materials used and so on. The 
waste is caused by the following: packaging that is too big for consumer needs or packaging 
that is too difficult to empty. Silvenius et al. (2013) claim that packaging solutions that 
minimise waste generation in households as well as in the forward chain will lead to the 
lowest environmental impacts. Therefore, it is important to design packaging that protects 
products properly and allows the customers to use the product completely.  
 
The above characteristics have impacts on all other aspects of a RL system, and the impacts 
are discussed accordingly in the following sections. To best manage household waste, we 
propose informed practices in Section A of Table 3, under the “What” aspect.  
 
How 
The “how” aspect is at the heart of RL, and investigates how value is recovered from returned 
products. Activities that constitute the most common procedures of RL include 
return/collection, inspection/selection/sorting, and defining reprocessing strategies which are 
distinguished as (Thierry et al., 1995):  1) direct reuse (and re-sale); 2) product recovery 
management (repair; refurbishing; remanufacturing; parts retrieval; materials recycling); and 
3) waste management (incineration and land filling).  
 
The choice of collection methods is dependent on reprocessing strategies, cost of recovery, 
type of product, population of users, location of users, collection routes, transportation modes, 
etc. (Hanafi et al., 2008). Typical collection methods include manufacturer collection from 
consumer, retailer collection from consumer and third party collection from consumer 
(Savaskan et al., 2004). Collection methods are further classified by whether the initial 
transport is performed by the consumer, or by a waste management company (Jahre, 1995). 
In the UK, household waste is usually collected by local authorities via a weekly kerbside 
collection service, or returned to local recycling centers by residents. Products containing 
hazardous materials need special collection methods.  
 
The definition of reprocessing strategies depends on the type of returns, the design of the 
remanufactured product or the type of recovered materials/energy, current manufacturing 
processes and capabilities, as well as the cost-benefit analysis (De Brito and Dekker, 2004). 
The outcomes of RL activities affect supply management in companies, which concerns the 
reuse of retrieved parts and materials to reduce the consumption and costs of raw materials 
(Dowlatshahi, 2000; Thierry et al., 1995). Through cost-benefit analysis, the benefits gained 
from reprocessing returned products should outweigh associated operational costs, landfill 
and contingent liability costs (Stock 1998). Environmental concern is also a factor affecting 
the choice of reprocessing strategy. Lansink’s ladder offers an order of preference for 
recovery options for returned products (Figure 1). Those which reuse more of the functional 
contents of a product are claimed to be more environmentally friendly (Duflou et al., 2008).  
 
Recovery options are simpler and more straightforward for EoU returns compared with EoL 
returns. EoU returns have the potential of generating monetary benefits through resale or 
reuse (Ravi et al., 2005), whilst there is an order of favourable resource recovery options for 
EoL returns, as proposed by European Commission: reuse of an EoL product, 
remanufacturing, parts retrieval and material recycling (Goggin and Browne 2000).  
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Value can not only be recovered from returned products, but also from the packaging 
materials (Dowlatshahi, 2000), which becomes an economic driver to actors in engaging RL 
activities. To reduce waste generation, cost and resource consumption, the European 
Directive 94/62/EC on packaging and industrial waste materials requires manufacturers to 
recover part of the packaging and waste related to marketed products (Gonzalez-Torre et al., 
2004).  
 
The literature reviewed above underpins our proposition on the reprocessing strategies for 
household waste, as summarised in Section B in Table 3.  
 
Prevention of waste
Reuse of products
Reuse of components
Material recycling
Incineration with energy recovery
Incineration without energy recovery
Landfill
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p
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Figure 1 Lansink’s ladder of recovery options 
 
Who  
The aspect of “who” concerns actors and their roles in a RL system. Actors can be 
distinguished as (Fuller and Allen, 1997): actors in the forward chain (supplier, manufacturer, 
wholesaler and retailer); specialised players in the reverse chain (third party RL service 
provider, organisation responsible for compliance scheme); opportunistic player (charity 
organisation); and sender or giver (customers who return products). Actors have different 
objectives and roles (De Brito and Dekker, 2004); some actors organise activities in the 
reverse chain, some execute tasks in the chain, and some do both. For example, 
manufacturers from the forward chain may be voluntarily responsible for recycling 
components or materials from returned products in order to reduce the cost of supply; they 
can also be made responsible by legislation for taking back returns to reduce waste and 
protect the environment.  Third party organisations launch compliance schemes to generate 
awareness, as well as to help manufacturers and retailers complete RL operations. Customers 
are usually the sources or senders of product returns, as well as being the clients of 
remanufactured products (Srivastava, 2008).  
 
Actors’ compliance in fulfilling their duties is essential to RL operation and success. On the 
other hand, designing a return-friendly RL system will stimulate and enhance actors’ 
compliance in this process (Xie and Breen, 2012). This, coupled with encouraging customers 
to proactively reduce waste, should achieve a high return on the investment of a newly 
designed RL system.  
 
Good cooperation and relationships among the actors facilitate RL implementation, and a 
higher level of coordination between the actors will, in turn, lead to increased performance in 
a RL system (Flygansvær et al., 2008). Therefore, total involvement and cross-sector 
collaboration from all the actors in the RL system are needed to minimise the total 
environmental impact of a business (Van Hoek, 1999). To improve engagement and stimulate 
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cooperation from actors, we make propositions in Section C of Table 3 as to “who” should 
take specific roles in managing household waste.  
 
Where 
The “where” aspect is about the physical network structure where the actors are located and 
the products are collected and processed. The locations of actors have an impact on the 
collection and flow of returned products. Modeling aspects relevant for RL network designs 
have been well studied in quantitative RL literature, with the aim of minimising the total cost 
(such as investment, processing, transportation, disposal and penalty costs)  (Fleischmann et 
al., 1997; Srivastava 2008; Yu and Wu, 2010). Constrained by time and availability of data, 
our research presents preliminary analysis as to how the number and location of collection 
centers help to enhance the convenience of collection and maximise the return rate of 
household waste (Biehl et al., 2007).  
 
Mechanisms and facilities provided to individuals influence the convenience of, and effort 
put into, recycling, which ultimately has an impact on household recycling behavior 
(including properly disposing of waste) (Barr et al., 2001).  Furthermore, the location, the 
number of collection points, the average transport distance for the customer and the number 
of households covered by one collection point are more precise criteria that affect the service 
level of a collection scheme and household recycling behaviour (Jahre, 1995).  The 
Environment Agency in the UK requires local authorities to be responsible for household 
waste collection and recycling. To increase recycling rate of household waste, local 
authorities in the UK provide weekly kerbside collection service and operate household waste 
recycling centers (HWRCs).  A nationwide RL system with widely spread collection points 
encourages residents to be more engaged with recycling (Erol et al., 2010).  
 
However, it is worth pointing out that  operating collection centers accounts for a large share 
of total costs (Jahre, 1995), and the effectiveness of collection centers is influenced by the 
locations, the number of centers, the capacities, and the actors who are responsible for the 
centers. In this aspect, the lack of funding and increment of responsibilities prevent 
companies from taking ownership of collection centers (Rogers and Tibben-Lembke, 2001).  
 
Instead of making heavy investment in dedicated resources, companies may wish to : 1) 
outsource the RL activities to the third party providers (Min and Ko, 2008) who set up 
nationwide collection networks, or 2) use existing HWRCs to shift the risk and save 
significant equipment and infrastructure costs (Erol et al., 2010).  
 
Based on the discussions above, in Section D of Table 3, we recommend good practices in 
setting up collection centers to manage household waste.  
 
Why 
The aspect of “why” is about the driving forces behind companies or individuals to become 
active in RL. There is a distinction between incentives used to influence the return of 
products and incentives used to influence the acceptance of products. Drivers for receivers 
include economic factors (Stock, 1998; Andel 1997), legislation ( Rogers and Tibben-
Lembke, 2001; Carter and Ellram 1998), Corporate citizenship (Alvarez-Gil et al., 2007) and 
environmental and green concerns (Rogers and Tibben-Lembke, 2001; Dowlatshahi, 2000), 
while reasons as to why senders return vary between manufacturing returns, distribution 
returns and customer returns (De Brito and Dekker, 2004).  
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Household waste is classified as EoU or EoL customer return. Customers’ expectations on 
receivers accepting these returns form an important noneconomic aspect of customer service 
(Dowlatshahi 2000; Andel 1997).   Customers can be less engaged in EoU or EoL returns as 
they are not required to be engaged or do not get enough benefit from it. Research findings 
suggest that enhancing public awareness of environmental protection and conservation can 
have a significant influence on increasing product returns from consumers (Erol et al., 2010; 
Prahinski and Kocabasoglu, 2006), thus pushing the implementation of a RL system and 
achieving both economies of scale and sustainable development. Setting up an approved 
compliance scheme has also proven to be successful in enhancing public awareness of the 
necessity of reducing and recycling household waste.  
 
Based on the literature review above, we propose incentives in Section E of Table 3 to 
enhance actors’ engagement in RL activities for household waste.   
 
3.2 Benchmarking process 
The RL of batteries recycling (including household batteries) has received great attention 
from academic researchers, practitioners and governments. Bartels (1998) describes the setup 
and organisation of the Dutch nationwide system for recycling batteries. Faria de Almeida 
and Robertson (1995) investigate how a German battery manufacturer manages returned 
batteries in the UK by paying disposer fees for return to a collection point, while Kannan 
(2009) proposes a structured model for selecting the best third party RL provider for the 
battery industry. Zhou et al. (2007) analyses battery recycling practices in China and 
identifies obstacles and weaknesses in performance. They recommend adopting a better and 
more practical approach by benchmarking the Chinese battery recycling system against those 
in USA and European countries, and advocate focusing on reviewing legislative action, 
technical guidance and improved RL infrastructure.  
 
The EU Directive 2006/66/EC on batteries came into force in 2006 requiring producers to 
take responsibility for the collection, treatment and recycling of batteries. Producers include 
manufacturers, wholesalers, retailers and those who import products for sale in the EU.  The 
UK is required to achieve a battery recycling rate of over 45% by 2016; to achieve this target, 
compliance schemes have been launched to raise awareness of the need to recycle batteries 
and to publicise collection arrangements. The directive and regulations enforce 
responsibilities on all entities, and a well-developed RL system has been established for 
recycling and reusing waste batteries, which has resulted in a battery recycling rate of 42% 
(ERP, 2010).  
 
Reducing, reusing and properly disposing of waste medicines require an increase in 
awareness of this issue, and an associated increase in activity and support. The aim of both 
RL systems is to recover and dispose effectively of waste material. However the practice by 
which this is achieved differs. The batteries RL system appears to be more structured and 
effective in engaging actors and achieving customer buy-in and uptake. One way of 
improving the operational efficiency and effectiveness of a RL system is to benchmark return 
operations with functional leaders (Blumberg, 1999), and identify and incorporate best 
practices into operational action plan to improve competence (Min and Joo, 2006).  
 
A comparison under the RL framework reveals that similarities exist between the two 
systems (Table 4).  Considering that research on RL processes for household waste medicine 
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is limited, and best practices in the industry are not well identified, the waste medicines RL 
system is benchmarked against a more established battery RL system.  
 
Insert Table 4 here 
 
4 Research methodology 
The research was conducted by combining a thorough literature review with empirical work, 
benchmarking method, survey and interviews, in seven steps (Figure 2): 
1. The RL system for household batteries was constructed based on literature review.  
2. The first round of interviews was conducted with 16 interviewees listed in Table 5.  
3. The results from the first round of interviews were triangulated by observations at 
pharmacy sites and analysis of secondary resources. The triangulated findings 
provided the backbone for the construction of the RL system for household waste 
medicines.  
4. The testable propositions developed in Table 3 are compared with the practices of the 
two RL systems constructed in Steps 1 and 3, to determine their generalisability and 
applicability.  
5. A benchmarking exercise was conducted for the two RL systems, exploring the gaps 
in best practices; propositions verified by the batteries RL systems are recommended 
to bridge the gaps.   
6. The survey results provided by Dynamic Group were used to assess the impacts of 
some recommended practices.  
7. To assess the viability of other recommended practices identified from benchmarking 
process, a second round of interviews was conducted with 13 interviewees (as listed 
in Table 5) and a personal street intercept survey was conducted with end users of 
medicines.  
 
Recommended 
best practices
Step 1. The 
first round of 
interviews
Step 2. 
Observation at 
pharmacy sites
Step 2. Analysis 
of secondary 
resources
Existing RL for 
household waste 
medicines
triangulation triangulation
Existing RL for 
household batteries
Step 3. 
Literature 
review
Step 5. 
Benchmark 
process
Gaps in best 
practices and 
recommendations
Step 6. Analysis 
of secondary 
data provided by 
Dynamic Group 
Step 7. High 
street survey and 
the second round 
of interviews
Step 4. Test 
propositions
 
 
Figure 2: Research design and processes 
 
4.1 The first round of interviews 
The first round of interviews were undertaken with 9 community pharmacists working in UK 
pharmacies including nationwide pharmacy multiples, regional chains and independent 
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pharmacies, supplemented by data from one PCT (as was in operation in 2012) committee 
representative, 3 General Practitioners, 1 NHS procurement manager, 1 product manager in a 
pharmaceutical manufacturing company, and a director in Dynamic Group, a social 
marketing company that has an interest in reducing waste medicines (see Table 5).  
 
Insert Table 5 here. 
 
A semi-structured interview guide was constructed under the RL framework in Table 1. The 
questions posed to participants aim to determine the current practice of product returns and 
disposal and the causes of waste generation. The information reported in this research is seen 
by the interviewees as a true reflection of the RL system in operation in NHS community 
pharmacies, considering that community pharmacies are managed and regulated centrally by 
CCGs who follow the same national guidance and regulations.  
 
4.2 Benchmarking method 
There is no single benchmarking process that has been universally adopted, but a typical 
benchmarking process consists of four phases: planning, analysis, integration and action 
(Camp, 1995). The first three phases were investigated in this research:  
i) Planning: the process to be benchmarked is the household waste medicines RL 
system, defined by the RL framework in Table 1. The performance metrics are 
defined as the awareness of the necessity, importance of reducing, reusing and 
properly disposing in the selected industry sector, the availability of the RL service, 
and the level of engagement and compliance from actors.  Similarities between waste 
medicine RL system and batteries RL systems act as grounds on which batteries RL is 
chosen as the benchmarking partner (Table 4). 
ii) Analysis: the main purpose of this phase is to identify the gaps between the two 
systems, the causes of gaps in the initiator company (waste medicines), and the 
enablers of best practices in the benchmarking partner (waste batteries). Under the RL 
framework (see Table 1), the operational practices of the two RL systems selected in 
phase i) are compared with the testable propositions , and propositions verified by the 
two systems are compared again to identify gaps under each dimension of the RL 
framework.  For each gap, the causes are explored through in depth interviews, and 
enablers for the good practices in battery RL are identified from the literature review. 
iii) Integration: the gaps, causes and enablers obtained in phase ii) are communicated to 
gain acceptance. In line with the research aim, the best practices are identified from  
the household batteries RL and: i) are compared with the survey results obtained from 
Dynamic Group, checking if best practices such as publicity campaigns have an 
impact on changing end user behaviour of ordering medicines and disposing of waste 
medicines; ii) are communicated with a sample of end users through a survey, 
checking if they could be driven to be more compliant in returning waste medicines if 
the best practices are implemented; and iii) are repurposed as thought-starters and 
consulted with healthcare professionals in the second round of interviews, who rate 
the practices in terms of viability measured by effectiveness and likelihood of 
implementation.  
 
4.3 The second round of interviews and high street survey 
The viability and feasibility of the recommendations are evaluated through in-depth 
interviews with healthcare professional and surveys with end users of medicines. 
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4.3.1 The second round of interviews 
To obtain experts’ views on the recommended practices, and screen out the practices that are 
deemed to be inappropriate, such as directly reusing returned medicines in the UK, the 
second round of interviews were conducted with 13 interviewees; 5 are new and the others 
are from the first round of interviews (see Table 5). Constrained by distance and availability 
of interviewees, e-mail interviews were undertaken with the PCT committee representative 
(Interviewee 21) and the staff from councils (Interviewees 19-20). Face to face interviews 
were conducted with the other interviewees.  
 
4.3.2 High street survey with end users of medicines 
The recommended practices outlined from the first round of interview were used to construct 
a survey instrument to assess the influences on end users’ intentions of dealing with waste 
medicines. The survey instrument consisted of three sections of questions that were 
completed by yes/no response statements, and coded box items. The first section focused on 
respondents’ demographic information, the second section identified respondents’ current 
practices of dealing with waste medicines, while the third section assessed respondents’ 
attitudes towards the recommended practices.   
 
A pilot study was conducted with 15 respondents in South East London and some minor 
changes were made in wording before launching the main study. A total of 300 individuals in 
Greater London were approached for the survey, from which 300 questionnaires were 
collected with 279 valid responses, a high response rate of 93%. All the 279 respondents have 
been medicine users and are primarily of relevance to the research, which increased the value 
of the survey.  
 
5 Findings  
This section presents RL systems constructed from Steps 1-3. Both systems are further 
reviewed to highlight synergies and disparities.  
 
Under the RL framework, the waste medicines RL system is benchmarked against a battery 
RL system, and the practices within these two systems are compared in Table 6. The 
benchmarking analysis reveals that the RL system for batteries is a more ‘caring’ and more 
effective system. It is ‘caring’ in the sense that it has more supporting legislation to 
encourage higher levels of engaged actors with higher awareness of the necessity and 
importance of recycling batteries, and effective as it has a higher return rate of used batteries. 
Based on this premise, gaps in the waste medicines RL system are identified (Table 6). The 
best practices are recommended, provided that they are verfied by the waste batteries RL 
system and supported by the participants in the high street surveys or the second round 
interviews.  
 
Insert Table 6 here. 
 
To ensure continuity in this discussion,  the analysis undertaken is based on the RL 
framework presented in Table 1.  
 
5.1 Existing RL system for household batteries 
The exiting RL for household batteries is constructed through literature review and shown in 
Figure 3: 
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Figure 3: Existing reverse logistics system for household waste batteries 
 
Propositions presented in Table 3 are well established in the exising household waste battery 
RL system (see Table 6), driven by the EU directive on waste batteries (EU Directive 
2006/66/EC). 
 
5.1.1 What: product 
In this aspect, propositions A1-5 presented in Table 5 are verified (see Table 6). A1) Waste 
batteries contain components such as metals (Lithium, Zinc, Lead), chemicals (Mercury 
Oxide etc.) and plastics. A2) Waste batteries have residual value left, and are more likely to 
enter the RL processes (Zhou et al., 2007), where thousands of tonnes of metals, and 
components of the “black mass” can be recovered, and plastics are reprocessed.  A3) Due to 
the presence of hazardous components, waste batteries need separate collection and treatment. 
A4) Waste batteries are of small sizes and easy to store at home.  A5) Multiple package sizes 
are available for sale ranging from 2 to 50 batteries in a pack, and can meet different 
consumer needs; economic loss resulting from unused batteries can, therefore, be reduced. 
The overall recycling rate is at least 55% of the gross weight of the batteries treated, which 
reduces the need to mine new materials, cuts CO2 emissions and saves resources 
(BatteryBack, 2013).   
 
5.1.2 How: processes and activities 
Returning batteries is easy, as propositions B1-2 have been implemented: B1) A nationwide 
battery RL system has been set up providing more widely spread collection points. B2) 
Returned batteries are sent to sites to recycle the metal parts and the different components of 
the "black mass", and reprocess the plastics.  
 
5.1.3 Who: actors 
Propositions C1-3 have been implemented to engage every actor in the batteries RL system. 
C2) Five compliance schemes have been approved for battery recycling, and they not only 
provide complete collection, gate-keeping and disposition operations, but are also responsible 
for publicity campaigns (Environment Agency, 2013). C1) The producers register with the 
schemes as members and pay them to fulfil their obligations. C3) Many organisations like 
schools are also involved in the scheme, and they not only offer drop off bins, but also deliver 
education on battery recycling to pupils in schools, who then educate parents to be compliant 
in recycling batteries.    
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5.1.4 Where: network structure 
To achieve the target recycling rate for batteries, propositions D1-2 have been implemented 
to improve recycling convenience. D1) A RL network has been set up with easily accessible 
collection points throughout UK. The Batteryback compliance scheme should provide 50,000 
collection points by the end of 2013 (Batteryback, 2013). D2) Together with recycling points 
provided by other compliance schemes and HWRCs operated by local authorities, the RL 
network for waste batteries recycling should soon have more than 100,000 collection points.  
Having outdoor collection points removes the limitation imposed by opening hours. 
 
5.1.5 Why: drivers 
All the seven proposed drivers E1-7 are identified in the batteries RL system. E1 and E7) The 
UK government could face fines of millions of pounds if the target recycling rate (over 45%) 
is not met by 2016; these fines will be passed to battery manufacturers which, in time, will 
raise the price of batteries to customers. E2 and E5) Therefore, the directive and regulations 
enforce certain responsibilities on all the actors in the battery RL system except individual 
customers, requiring producers to incorporate waste management practice at the three levels: 
reduce, reuse and recycle. E1, E3, E4 and E6) The five battery compliance schemes in the 
UK are working together to achieve the target recycling rate (Environment Agency, 2013), 
and they have launched publicity campaigns, which aim to educate the public reducing 
resource costs and protecting the environment, while facilitating producers setting up 
corporate green images. E4) The success of the publicity campaigns is proved by significant 
behaviour change in the recycling of household batteries, with two in five people (42%) 
having recycled a battery (ERP, 2010).  
 
Communication on battery recycling is rich and diverse, and there has been a comprehensive 
and continuing information campaign to increase the battery recycling rate. Information on 
battery recycling can be found in 83% (368 out of 445) of local authorities’ websites, on 
television, in the premises of retailers, and on outdoor recycling banks.   
 
5.2 Existing and recommended RL system for household waste medicines 
The results from Steps 2 and 3 provide an insight into the RL system in community 
pharmacies, as shown in Figure 4: 
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Figure 4: Existing reverse logistics system for household waste medicines 
 
Propositions in Table 3 are less well implemented in the household waste medicines RL 
system, when compared with the waste batteries RL, and gaps are identified (see Table 6).  
 
5.2.1 What: product 
Existing practices 
As a product, propositions A1, A3 and A4 are verified in waste medicine. A1 and A3) Waste 
medicines contain chemicals that are harmful to the environment if not properly disposed of, 
and require separate collection and treatment. The medicines may still have functionality if 
the expiry date is not passed. A4) Due to the small sizes, waste medicines are easy to store in 
a cupboard or be disposed of inappropriately (for example, flushed into the sewage system). 
Most medicine packs contain 28, 30 or 31 days medication, which will lead to medicine 
waste since the majority of NHS prescription periods are 28 days. Strict policies in the UK 
regulate that all returned medicine must be destroyed and cannot be re-used, which means no 
commercial value can be recaptured from the RL for household waste medicine.  
 
The proposal of reusing waste medicine has been controversial (DoH, 2010). A majority of 
interviewees in the first round (54%, 7 out of 13) argued that returned medicines should 
require permission for reuse if they are intact, in good condition and in date. InterCare is a 
UK registered charity which collects unused medications from General Practitioner (GP) 
surgeries in the UK and then delivers them free of charge to over 100 health centres in 7 
countries in sub-Saharan Africa (InterCare, 2012). According to the interviewed 
pharmaceutical product manager (Interviewee 15), some pharmaceutical industries in France 
are responsible for collection and reuse of waste medicines.  However, other interviewees, 
especially pharmacists, strongly object to the idea of reusing dispensed medicines due to 
quality and safety concerns.  
 
Gaps and recommended practices 
Statistics from the high street survey and BBC News Health (2012) indicate that there is a 
secondary market for returned medicines in the UK as over half of people would be likely to 
take returned pills (see Table 7). The technology is available to scan returned medicines 
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electronically and verify that they are still in good condition (Mackridge and Marriott, 2007). 
Therefore, it would be possible to propose A2, i.e., reusing at least some of these medicines.  
 
The product manager in the second interview recommended that “medication pack sizes can 
be synchronised, based on the advice from the National Prescribing Centre”, to enable 
smaller but more frequent doses to be dispensed by pharmacies, thus reducing the amount of 
unnecessary medication in circulation. This practice is our proposition A5, which is evident 
in other countries, e.g. shorter prescription periods (7-14 days) have been trialled in Canada 
(Paterson and Anderson, 2002).  
 
Insert Table 7 here. 
 
5.2.2  How: processes and activities 
Existing practices 
The findings indicate that none of the propositions in this dimension has been implemented. 
Medicines returned to pharmacies are disposed of with the obsolete medicines generated from 
pharmacy stock (quoted as 0.05% by Interviewee 3), using the same waste bins provided by 
the PCT.  PCTs utilise a contractor to dispose of waste. The waste medicines are made safe 
by clinical waste incineration at an authorised incinerator.   
 
An outlier to the main stream activity is the internet pharmacy. A pharmacist respondent, 
Interviewee 4, stipulated that as a pharmacy provider accessed via the internet, “….patients 
cannot access our premises. Our website does however outline the procedure for arranging 
collection of waste medicines from patients should that be required”.   
 
Gaps and recommended practices 
In both waste medicines and batteries RL systems, reverse flows rely on end users’ returns 
rather than collection by contractors, which influences the return rate and quantity. A more 
proactive approach would be to use the existing domestic waste service to collect waste 
medicines, facilitated by a compliance scheme (Interviewees 19 and 20). Since 1974, 
InterCare have sent nearly £11 million worth of surplus medicines as aid to Africa, and the 
donated medicines have treated millions of people who otherwise not have access to medical 
treatment (InterCare, 2012). Proposition B2 is therefore recommended, i.e., donating surplus 
medicines to under-developed countries as long as the medicines  comply with the World 
Health Organisation guidelines on medicine donations.   
 
Materials recycling and component reuse are the recovery options in the batteries RL system, 
while the recovery option for household waste medicine is incineration, making it less 
environmentally friendly or economically efficient. Proposition B3 “recycling packaging 
materials from waste medicines will certainly enhance the environmental friendliness” of the 
recovery option (Interviewees 14).  Respondents in the second interviews acknowledged the 
potential positive impacts of proposition B1, i.e., investigating and initiating a compliance 
scheme which collects and treats waste medicines on behalf of CCGs and manufacturers. 
 
5.2.3 Who: actors 
Existing practices 
Proposition C1 has been less well implemented in the existing household waste medicines RL 
system, as not everyone is fully engaged in the reverse activities they are assigned to. The 
DoH is responsible for regulations and policies on waste medicines management; the CCG is 
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coordinated by GP practices and is responsible for arranging for contractors to collect waste 
medicines from pharmacies; and pharmacies accept waste medicines returned by end users. 
Although pharmacies do this as part of their contract, they “do not have economic incentives 
to do so” (Interviewee 13). The same sentiment could be applied to end users concerning 
their lack of activity in returning waste medicines as they are not obliged or motivated to do 
so.  
 
Gaps and recommended practices 
Medicine Waste campaigns organised by the Dynamic Group in 11 UK regions led to 
positive changes in end users’ behaviour relating to ordering repeated medicines and 
disposing of waste medicines.  The findings from the survey of medicine users also verify 
that they are likely to change their behaviour due to direct communication and education 
from healthcare professionals (see Q.2 in Table 7). 
 
In addition to the end users, we propose the implementation of C1, i.e., every producer of 
waste “should work together so that we collectively reduce waste" (Interviewee 16). 
Implementing propositions C2 and C3 by performing RL activities under the responsibility of 
a consortium, for example the CCG, along with a few leading companies, such as companies 
that run a compliance scheme, could make it more cost effective to implement the RL system.  
 
5.2.4 Where: network structure 
Existing practices 
At present, only community pharmacies and GP surgeries take back waste medicines, and 
none of the propositions to improve convenience of returning/collection has been 
implemented.   There are around 12,175 community pharmacies in the UK, and 10,112 GP 
practices (British Medical Association (BMA), 2012). The provision for returning waste 
medicine is constrained by the numbers of collection points (22,287 in total), the locations 
(99% of population get to a pharmacy within 20 minutes by car and 96% by walking or using 
public transport), and the opening time (pharmacies open 40 hours/week or 100 hours/week 
under exemption, while 77.1% of GP surgeries open 53 hours/week). The constraints have a 
significant impact on the behavior of the 35-54 age group who contribute most to the 
generation of waste medicines.  
 
Gaps and recommended practices 
The findings from the survey prove that there is a significant level of inconvenience due to 
inadequate access to collection points (see Q.3 in Table 7), which, to a large extent, prohibits 
or reduces end users’ compliance in returning waste medicines.  A full clinical waste 
collection service is offered by the two councils where Interviewees 19 and 20 serve, at no 
cost to the residents. As summarised in Table 6, the design and provision of optimal 
collection could enhance end users’ compliance in returning (propositions D1 and D2).   
 
5.2.5 Why and why not: drivers 
Existing practices 
None of the proposed drivers has been identified in the existing waste medicines RL system. 
In the UK there are formal rules and guidance governing pharmacies or GPs accepting 
pharmaceutical waste, but not stimulating or enforcing them to actively take action. There is 
no regulation or directive on implementing an end user return system. Communication on 
managing household waste medicines is limited. Although governmental websites (for 
example, Directgov) list information on how to dispose of waste medicine, only 84 out of 445 
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(i.e., 19%) councils classify waste medicine as hazardous waste and advise residents to return 
them to pharmacies. The interviewed pharmacists indicated that communication between end 
users and community pharmacists concerning returning medicines waste is not consistent. 
Some respondents stipulated that they are informed of returns on completing a transaction but 
some are not, and the same comments were made by participants in the high street survey. 
 
According to the DoH (2011), approximately £1 in every £25 spent on NHS medicines is 
wasted, but this message has not been passed to the public for their attention. The interviewed 
GPs claimed that there is a lack of financial awareness or incentives to encourage end users to 
return medicine waste. Community pharmacies are paid via their GP/CCG contract to accept 
returns but not paid to analyse reasons for return or find ways to reduce waste, so they are 
less incentivised to encourage returns. Although community pharmacies attempt to influence 
end users to return waste to prevent stockpiling or health and safety issues arising, the 
approach to this is not standardised across all pharmacies but is at the discretion of the 
pharmacy staff member. 
 
Gaps and recommended practices  
In both household waste medicines and batteries RL systems, end users need to be motivated 
to return waste products, while the other actors in the system need to be stimulated or 
enforced to take them back.   
 
As shown in Table 6, gaps between the two RL systems are identified in the aspects of 
legislation/directive, compliance scheme, communication and financial incentives.  
  
Although proposition E2 has been used as an impetus for establishing a RL network and 
driving companies to implement RL activities (Rogers and Tibben-Lembke, 2001), 
introducing new legislation or a directive requiring end users to return waste medicines is 
deemed to be impractical in the short term. In the waste medicines RL system, the situation 
can be improved by implementing E4, i.e., by enhancing public awareness or by healthcare 
professionals or government educating end users on the need for, and ways of, waste 
medicines reduction and proper disposal. As a result of the campaigns launched by Dynamic 
Group, at least 25% of 7022 respondents to the survey now claim to have changed how they 
order their repeat prescriptions, i.e., only order what they need. A similar proportion of 
respondents claim returning unwanted medicines to pharmacies because of the campaigns.  
 
The findings from the high street survey reveal that direct communication with GPs or 
pharmacists work more effectively than leaflets or posters in encouraging end users to return 
waste medicines to pharmacies (see Q.4 in Table 7). The GPs and pharmacists in the second 
round of interviews support incentivising closer professional management of medicine supply 
at the point of dispensing to achieve lower waste targets.  
 
Lack of economic incentives are also emphasised as a barrier to actors engaging in RL 
activities (Blumberg, 1999). Reusing returned medicines generates monetary benefits and 
could act as a strong driver, incentivising all the actors engage in the reverse activities 
(proposition E1). The interviewed pharmacists (Interviewees 1-2 and 7) recommended 
proposition E5, i.e., retrieving medicines to determine waste levels and instigate waste 
management strategies at three levels: reduce, reuse and properly dispose of. Targets may be 
put in place aligned with national or regional waste medicines reduction figures.  This activity 
can be outsourced to a third party company, e.g., via compliance schemes coordinated by the 
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Environmental Agency (proposition E6). The interviewed GPs and Pharmacists indicate that 
they would be more cost conscious in prescribing and dispensing should a financial fine be 
introduced if waste medicines were above the predetermined target (proposition E7); they 
would also be more active in educating end users about waste medicines. 
 
Proposition E7 can also be implemented by introducing a limited charge to all prescription 
items, or having a label attached showing the full cost of medicine is also suggested in order 
to reduce the likelihood of waste (Australian Government, Department of Health and Ageing, 
2012). The high street survey further verifies the likely impact of raising cost awareness (see 
Q.5 in Table 7).  
 
6 Discussions and managerial implications 
The propositions presented in Table 6 have proved to be successful in creating a more 
‘caring’ and more effective waste batteries RL system. How this has impacted on higher 
levels of engagement, more awareness of the necessity and importance of reducing and 
recycling, and a higher return rate in this RL system is unclear. Significant opportunities do 
seem to exist for a waste medicines RL system that seeks to reduce waste and cost, including 
product value, processing approaches, system co-operation and enforcement, drivers and 
motivations, and system design and facilitation.   
 
The findings of this study indicate that there are key outputs which impact on RL system 
design and delivery. These are presented as follows: 
 
Product value: - the residual value left in a returned product has a direct and positive impact 
on actors’ engagement in RL. Since no commercial value can be recaptured from waste 
medicines, this causes hesitation and reluctance from the actors in the PSC to implement the 
RL processes (Prahinski and Kocabasoglu, 2006). This is a quite a significant finding since it 
in turn inhibits initiatives to invest in RL infrastructure and information systems, and limits 
the scope for collaboration among actors. Apart from recycling packing materials, it seems to 
be difficult to “create” residual value in returned medicines, due to strict regulations and 
health and safety concerns. Reuse of good condition medicines is encouraged since it not 
only reduces material wastage, but also acts as an incentive, motivating actors to engage in 
the reverse activities. However, the impact of actual cost savings per returned product for the 
NHS could be small. Sorting and separating processes for returned medicines can be complex 
in practice, and often only a minority of products are intact, in good condition and in date 
(DoH, 2011). This means that the extent to which reuse of medicines could affordably reduce 
the cost of NHS medicines wastage is likely to be very small.  More effective savings would 
be generated from greater standardisation on medicine pack sizes, improved prescribing 
patterns (product type and quantity), and inventory management within pharmacies. All of 
which would reduce avoidable waste in a cost effective manner. 
 
Processing approaches: - Both household waste medicines and household batteries are EoU 
or EoL returns initiated by end users, and are classified as public recycling which is oriented 
at avoiding waste and leads to a net positive benefit for the environment (De Brito and 
Dekker, 2004).  The main way of processing returned waste medicines is incineration, which 
is less economically efficient or environmentally friendly than other recovery options. It is 
not possible to change the processing strategy for waste medicine; however, it is reasonable 
to reduce the amount of avoidable waste and reuse or properly dispose of more of the 
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unavoidable waste (e.g. out of date, or opened packets/products). Launching a compliance 
scheme would make it easier to return or manage waste medicines, therefore encouraging 
actors to become more engaged. 
 
System co-operation and enforcement: - The success of a RL system requires cross-boundary 
cooperation among the actors within the whole reverse chain (Xie and Green, 2012). 
Benchmarking against the batteries RL system found that the superior performance is 
attributed to the higher levels of engagement from all the actors. In contrast, the attention and 
interest in reducing and properly disposing of household waste medicine decreases 
substantially from top management (DoH) to the end users. 
 
Discussions with healthcare professionals found that the lower levels of engagement are 
mainly due to the lack of obligations or financial incentives. Legislation and economic factors 
together determine the conduct of actors in the RL system, but these two factors are missing 
from the existing waste medicines RL system. In some countries, customers are required by 
law to return unused medication. For example, in Jefferson County USA, prescription 
medication should be separated from household pharmaceutical waste when being returned, 
and medication accumulated from more than one resource should be disposed of under 
national regulations (Grabow and Brachman, 2007). Imposed environmental protection 
regulations usually result in increased cost of products or services, as well as generating 
unwillingness to cooperate. Therefore, introducing new legislation or a directive requiring 
customers to return waste medicines is deemed to be impractical in the short term. 
Furthermore, not all the regulatory mandates have a substantive impact on the environmental 
disposal of the pharmaceuticals (Daughton, 2003).  
 
If enforcement cannot be applied through legislation, communication and education are found 
to be the key mechanisms to enhance public awareness, as well as to encourage positive and 
heightened environmental behaviour with regard to waste medicines (Erol et al., 2010; 
Prahinski and Kocabasoglu; 2006). Our survey shows that greater personal or direct contacts 
with end users will be more effective in encouraging their engagement in recycling activities 
than just disseminating information on recycling. These findings are in agreement with 
literature that argue that direct communication are more effective in order to gain ‘buy-in’ 
from customers in recycling schemes (Tucker and Speirs, 2002). If vigilance concerning 
wasted medicines is to be raised, then there is scope for wider publication of this issue, e.g. 
not only from NHS providers but also local authorities. For long-term sustainable 
development and competitiveness, regulations need to be set up to promote, control and 
standardise practices on reducing and properly disposing of waste medicines (Erol et al., 
2010); for example, standard practices on how pharmacies and GPs educate end users to 
return waste. The ultimate objective of communication and education is to encourage end 
users to voluntarily become stewards in promoting and performing better social and 
environmental practice, which is a more favoured approach than employing regulations and 
legislations (Daughton, 2003).  
 
Drivers and motivation:  economic benefit has been identified as one of the main drivers that 
motivates companies to adopt RL (de Brito et al., 2004). Business incentives, such as tax 
incentives and capital incentives, have resulted in environmental improvements (GEMI, 
2006). Since there is no residual value left in the waste medicines, an indirect financial 
incentive is proposed, i.e., setting up a statutory target for the amount of waste medicines to 
be produced and imposing fines on producers and, ultimately, on end users if the target is not 
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achieved. This incentive has been proven to work effectively in enhancing engagement and 
return rates in the waste battery RL system, but is hard to estimate the size of the effects 
achievable in the waste medicines system given that actors in the system, such as CCGs, are 
non-profit organisations and funded by central government.   GP respondents also argued that 
the waste target should not become a barrier to improving the overall health and wellbeing of 
health service users.  The role of the CCG is to commission services within a given 
geographic area and includes all GPs in this area.  Where once PCTs commissioned services 
and GPs adhered to this decision, GPs now determine what is best for their patient population 
and select their provider of choice. CCGs in April 2013 replaced PCTs as commissioners and 
now control a large proportion of the NHS budget. As such GPs within this group will 
oversee contracts for medicines disposal in community pharmacy and may be involved in 
designing returns channels to promote medicines return and retrieval for safe disposal. 
Another community based by-product of the CCG formation is the need to have GP 
surgery/practice representation at CCG forums to feedback on the content and deployment of 
policy and practice to patients. Funds are provided to all GP practices to develop and support 
patient groups. Such groups could be used to trial newly designed educational 
materials/systems to promote end users’ medicines returns.  
 
Compliance from individual customers can also be stimulated by proper incentive schemes 
(Deci et al., 1999).  Our findings advocate putting the price on every NHS medicine pack in 
order to raise awareness of costs, and thus encouraging reduction of wastage. This is a better 
supported proposal than direct charging since 80% of NHS patients do not pay for 
prescriptions and the latter proposal is thought to be unfeasible. The option of sending unused 
medicines to underdeveloped countries is also found to an incentive stimulating customers 
properly disposing of medicines. If it were thought that some form of reuse might be possible 
for expensive medicines, customers are more likely to take waste medicines to pharmacies 
(DoH, 2011). On the contrary, if customers know waste medicines are only incinerated, they 
tend not to take them back. The impetus appears therefore to be cost/economical (despite the 
fact that there is no value for this product at this stage in its life cycle) and less about safety in 
the home and relies heavily on Individual Social Responsibility (ISR). As purported by 
Bénabou and Tirole (2010) when exploring ISR and Corporate and Social Responsibility 
(CSR) people are driven by genuine instinctive altruism, respond to materials incentives and 
are also driven by social and self-esteem concerns. This observation is significant and 
important and needs to be maximised to increase the return of waste medicines.   
 
System design and facilitation: system inadequacy (Rogers and Tibben-Lembke, 2001; Erol 
et al., 2010), such as inadequate collection points, is also a barrier, making end users less 
engaged in the returns process. Some local authorities have begun to offer waste medicines 
collection services through HWRCs, and the wider development of this service across the UK 
is encouraged in order to increase volumes (the economics of collection, segregation, 
transportation and processing), and ultimately increase the degree of involvement in reverse 
SCs (Prahinski and Kocabasoglu, 2006).   
 
The findings under the five perspectives of the RL framework not only give context to a new 
waste medicines RL system, but their combination determines to a large extent the kind of 
issues that arise in implementing, monitoring and managing such a system.  
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7 Conclusion and future work 
For a number of years, the NHS (UK) has been working under a Quality, Innovation, 
Productivity and Performance (QIPP) agenda (DoH, 2010). “During 2011/12, the NHS made 
a total of £5.8 billion of QIPP savings, with £700 million associated with medicines use and 
prescribing. The QIPP medicines use and procurement work stream aims to ensure that value 
for money is further enhanced while quality of care is maintained or improved, by optimising 
the use of medicines” (NICE online , 2013). Cutting the amount of medicine waste has 
therefore been a priority for the DoH and associated governmental and professional bodies 
e.g. Royal Pharmaceutical Society, as it potentially could save millions of pounds that could 
be invested elsewhere. However, the interest in reducing and properly disposing of waste 
medicine deteriorates significantly from top management levels to individual customers and 
actors in the existing waste medicine RL. 
 
Similarities exist between the household waste medicine RL system and battery RL system, 
in terms of product, processes, actors, network structure and drivers. However, this research 
shows that awareness and return rates of battery waste are higher than those of waste 
medicines, and most importantly, the engagement from actors in battery RL is much greater 
and more active than those in waste medicine RL. The key cause for the differences is the 
support and enforcement from top management and regulatory authorities. EU directives 
place responsibilities on the actors in the battery RL to work together to achieve the target 
return rate, otherwise fines would be passed to producers and, finally, to customers. To 
improve the existing RL system for waste medicines, this paper benchmarks the household 
waste medicines RL system against the batteries RL system, and generates a profile of 
recommendations under the RL framework based on the best practices in battery RL. 
Strategically, critical drivers are identified to encourage and compel actors to participate in 
the waste medicine RL system, including incorporating practices at three levels, a compliance 
scheme, improved communication, and financial incentives. Operationally, improvement can 
be made within the PSC to proactively reduce waste (by professionals via more prudent 
clinical prescribing and end users when reordering repeat prescriptions), improve product 
management (synchronising medication pack sizes), enhance health and safety within the 
home (by encouraging and facilitating more effective waste returns), and recapture 
commercial value where possible (such as reusing good condition medicines and recycling 
packaging materials). Total involvement and cross-sector collaboration are needed from all 
actors in the system, which can be promoted by the drivers and a user-friendly RL network 
structure.  Such results as presented by NICE online (2013) can only be delivered by a 
uniform, orchestrated and strategic approach which has not only government and regulatory 
support, but also customer engagement and delivery. 
 
RL in pharmaceutical industries has been studied for B2B returns from participants within a 
PSC, or for by-products within the manufacturing plant. The academic research community 
would benefit from this research as it is focused on the under-researched area which is 
enhancing actors’ compliance in reducing, reusing and properly disposing of medicine waste 
and the systems/practices to achieve it. The research findings provide a step towards reducing 
an existing gap in pharmaceutical RL research to influence best practice.  The 
recommendations made in the paper not only aim to motivate actors to reduce medicine waste, 
but also use medicines effectively, placing an emphasis on improving health outcomes and 
meeting the medicines optimisation agenda in the NHS (NICE online, 2013). With the 
current restructuring of the NHS, there is even more need now than ever for GPs to take a 
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more proactive stance in medical prescribing, as they are now responsible for pharmaceutical 
spend and spending their funds in an efficient manner. The information gathered via the 
recommended practices can offer valuable inputs to inform prescribing practice and 
encourage more sustainable green decision making in the forward logistics, helping the PSC 
to become ‘greener’ in terms of procurement, operational management and distribution. 
External to the PSC, an improved household waste medicine RL system will facilitate the 
development of a safer community and domestic residences, free of unnecessary 
pharmaceutical waste and potential hazardous materials. This in itself makes the case for this 
system and the crucial role of engagement from all actors within it.  
 
The research limitations lie in how feasible it would be to implement the recommended 
practices, although they have gained acceptance from the interviewed pharmacists. While the 
interviewees in this study represent a wide and diverse range of relevant actors in the 
household waste medicine RL system, the sample remains relatively small in the context of 
the total number of healthcare professionals in the UK.  The high street survey was only 
conducted in London, and relied on self-reporting, which may lead to some under-reporting, 
and also some inaccuracies. Further interest will focus on the cost effectiveness of 
implementing the recommendations, i.e., whether or not the recommended practices can be 
addressed in a cost effective manner; that is, could the savings made from reduced medicine 
costs outweigh the costs of the practices.  
 
Future developments will measure performance and evaluate the appropriateness of 
recommended practices, and investigate practices that are less intensive or costly, but which 
can raise awareness of the importance of compliance in the waste medicine RL system.  
 
The outputs of this study indicate that that the operational design and practice of the 
household battery RL is more structured and effective in achieving its purpose (meeting 
targets for returned products) than the medicine RL system. If ‘caring’ (having the resources, 
support and incentive to instigate change) leads to winning, then the battery RL system 
currently wins every time. This paper highlights this issue and advocates learning from best 
practice in battery RL to improve the medicine RL design and execution and supports the 
current NHS agenda on medicine waste reduction (DoH, 2012).  
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Figures and tables: 
 
Table 1: RL framework (adapted from De Brito and Dekker 2004) 
Dimensions Definitions 
What 
(Products) 
The products entering the RL network (product-in’s) and the products leaving the RL 
network (product-out’s), 
How 
(Activities and 
Processes) 
The RL activities, including returning, collection, and main recovery processes (such as 
resale, reuse, redistribution, repair, refurbishing, remanufacturing, recycling, 
incineration, or proper disposal).  
Who 
(Actors) 
The actors and their roles in the RL network (supplier (the owners/users of the product-
in’s), collector, processor, customer and initiator). 
Where 
(Network 
Structure) 
The physical network structure where the actors are located and the products are 
collected and processed. 
Why and Why not 
(Drivers, Return 
reasons, Barriers) 
The drivers for the suppliers of the product-in’s and the initiator of the RL activities, 
and the barriers for those who do not take RL activities. 
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Table 2 Literature classification under the RL framework  
 
Literature 
 classification 
Dimensions of the framework 
What 
(Products) 
How 
(Activities and 
Processes) 
Who 
(Actors) 
Where 
(Network 
Structure) 
Why and Why not 
(Drivers, Return 
reasons, Barriers) 
i) Basic concepts and summary of RL 
- De Brito and Dekker, 2004; Rogers and Tibben-Lembke, 2001; Stock, 1998; 
 
√ 
 
√ 
 
√ 
  
√ 
ii) Enhance RL system and its performance 
- Quantitative models for RL (Fleischmann et al., 1997; Giuntini and Andel, 1995; 
Yu and Wu, 2010)  
- Improving RL system performance using manufacturing technologies (Giuntini and 
Andel, 1995), information technologies (Li and Olorunniwo, 2010; Daugherty et 
al.2005), resource commitment (Daugherty et al., 2005 ), or network design (Qin 
and Ji, 2010) 
- Frameworks (Genchev et al., 2011), decision making models (Tan and 
Kumar,2006), and formalisation processes (Autry 2005)for managing RL systems  
 
 
√ 
 
 
 
√ 
 
 
√ 
 
√ 
 
 
√ 
 
 
 
 
√ 
 
 
 
√ 
 
 
√ 
 
 
 
 
 
√ 
 
 
 
 
iii) Applications of RL in various sectors 
- packaging material (Gonzalez-Torre et al. 2004), bottling or glass (González-
Torre and Adenso-Díaz, 2006) 
- non hazardous products, such as paper (Pati et al., 2008), clothes (De Brito and 
Dekker, 2004)  
- Hazardous products, such as electrical waste(Lau and Wang, 2009), 
automobile(Daugherty et al., 2003 ),batteries (Kannan, 2009; Zhou et al., 2007; 
Faria de Almeida and Robertson, 1995, medicines (Xie and Breen, 2011) 
 
√ 
 
 
√ 
 
 
√ 
 
 
√ 
 
 
√ 
 
 
√ 
 
√ 
 
 
√ 
 
 
√ 
  
√ 
 
 
√ 
 
 
√ 
iv) Drivers and barriers of RL 
- Drivers: Alvarez-Gil et al., 2007; De Brito and Dekker  2004; 
- Barriers: (Ravi and Shankar, 2005) 
     
√ 
v) Specific issues in RL 
- distribution and warehousing (Andel 1997, Giuntini and Andel, 1995 ), 
- remanufacturing, repair, reconfiguration and recycling (Clendenin 1997) 
-  transportation (Jahre, 1995); 
  
√ 
 
√ 
√ 
  
√ 
 
 
√ 
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Table 3 Testable propositions for a household waste RL  
Dimensions  
Factors identified by 
Dowlatshahi (2000)  
Testable propositions 
A. What  
Overall quality 
Packaging 
 
1. Household waste differs in four characteristics: composition, deterioration, dimensional size and packaging solution.  
2. The four characteristics determine the residual value of a product. Products with residual value are more likely to be 
returned to and reprocessed in a RL system. It is proposed to find ways to “create” residual value in household waste, for 
example, use new technologies to retrieve materials. 
3. Household waste containing hazardous components need to be handled separately and properly.  
4. Small household waste tend to be stored or disposed through sewage system; while big household waste tends to be 
returned but are more challenging to be transported or handled. 
5. Waste can be generated if package size is larger than consumer needs, or package is difficult to empty. It is proposed to 
reduce waste by synchronising package size with consumer needs.  
B. How  
Cost-benefit analysis 
Transportation 
Warehousing 
Supply management 
Remanufacturing 
Recycling 
1. Organise an effective return and collection process through nationwide RL network.  
2. Choose a cost effective and environmental friendly reprocessing strategy to recapture value from household waste. Reuse 
EoU returns if appropriate, and choose recover option for EoL returns according to options proposed by European 
Commission.  
3. Recycle packaging materials. 
 
C. Who  
 1. Total involvement and cross-sector collaboration are needed from all the actors in the RL systems. 
2. Appoint a third party organisation to launch compliance scheme for publicity campaigns, and help other actors to fulfil RL 
duties.  
3. Involve organisations and businesses to educate and encourage waste holders to reduce and recycle household waste.  
D. Where  
 1. Outsource RL activities to a third party provider who setup nationwide collection network 
2. Utilise the network of existing household waste recycling centres (HWRCs) and deploy local collection systems  
E. Why 
and 
Why not 
Overall costs 
Customer service 
Environmental concerns 
Legislative concerns 
1. Encourage actors to reuse or recycle household waste for economic gains  (Economic factors). 
2. Enforce directives on reducing and recycling household waste (Legislation). 
3. Encourage organisations to participate in household waste management therefore to improve corporate image (Corporate 
citizenship). 
4. Enhance public awareness on the environmental impacts imposed by household waste (environmental and green concerns, 
public awareness). 
5. Incorporate waste management practice into contracts of organisations at three levels: reduce, reuse and recycle (or 
properly dispose of if no component can be recycled).   
6. Set up compliance schemes.  
7. Apply financial incentives, i.e., sharing the cost of waste management among all the actors, or enhance financial awareness 
on full cost. 
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Table 4 Similarities between the RL for household waste medicines and household batteries 
 
Table 5: Interviewee details 
Interviewees in the first round Role Location 
1-2 Qualified pharmacist Kent 
3-6 Qualified pharmacist Yorkshire 
7-9 Qualified pharmacist Essex 
10 PCT committee representative Kent 
11-12 General Practitioner Yorkshire 
13 General Practitioner Greater London 
14 NHS procurement manager Greater London 
15 Product Manager in a pharmaceutical manufacturer Kent 
16 Director of the Dynamic Group Scotland 
Interviewees in the second round Role Location 
17 Environment planner in borough council Cambridgeshire 
18 Environment planner in borough council Greater London 
19 Waste management contracts manager in borough council Yorkshire 
20 Waste management contracts manager in borough council Yorkshire 
21 PCT committee representative Cambridgeshire 
1-2 Qualified pharmacist Kent 
7-9 Qualified pharmacist Essex 
10 PCT committee representative Kent 
13 General Practitioner Greater London 
16 Director of the Dynamic Group Scotland 
 
Dimensions RL for household waste medicine and household battery  
 
What 
 both contain hazardous components, and need separate collection and treatment.  
 both are easy to be store at home, and easy to be disposed of inappropriately. 
How  separate collection and treatment. 
Who  end users, retailers, contractors, and professional and regulatory bodies need to become involved in both RL processes. 
Where  kerbside collection cannot be used, and end users need to return waste to the collection points.  
Why and Why 
not 
 motivate manufacturers, distributors and retailers to participate in the RL processes. 
 campaigns need to be launched to motivate the public to participate in the RL processes. 
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Table 6 Benchmarking household waste medicine RL against household battery RL  
Dimensions  
Propositions 
implemented in 
household waste 
batteries RL 
Propositions 
implemented in 
household waste 
medicines RL 
Gaps identified in waste medicine 
RL 
Best practices recommended  
A. What  
A 1-5  A1, 3-4 A 2. No commercial value is left in the 
returned waste medicines, so there is no 
product generated from RL. 
A 5. Waste is generated as prescribed 
amount exceeds end users’ needs.  
A.2  Recapture commercial value from waste medicines by 
reusing  approved medicines, e.g. donating them to 
underdeveloped countries.  
A.5 Reduce economic loss by synchronising medicine pack 
size and reducing unnecessary medication in circulation 
(reducing waste generated).  
B. How  
B 1-2  None  B.1 Returning is more difficult as 
collection points are not widespread.  
B.2 Returned medicines are incinerated. 
B.1 Launch compliance scheme collect and treat waste 
medicines on behalf of CCGs and manufacturers. 
B.2 Reuse approved medicines, e.g., donating them to 
underdeveloped countries.  
B.3 Recycle the packaging materials of waste medicines. 
C. Who  
C 1-3 C.1  C.1 Not everyone is engaged.  
C.2 There is no organisation that launch 
compliance scheme.  
C.3 GP surgeries and pharmacies do not 
educate end users to return waste 
medicines.   
C.1 Total involvement and cross-sector collaboration are 
needed from all the actors in the RL systems. End users 
become actors to reduce waste medicines.  
C.2 Appoint a third party to launch compliance scheme.  
C.3 GP surgeries and pharmacies not only offer a return 
service, but also educate end users to reduce and return waste 
medicines.  
D. Where  
D 1-2 None  The return of waste is limited by the 
number, locations and opening times of 
collection points. Collection is only 
available in GP practices and 
pharmacies, which are 22,287 collection 
points in total. .   
D.1 Appoint a third party to setup a nationwide collection 
network, providing outdoor recycling banks and bins in 
pharmacies. 
D.2 A wider collection network needs to be configured 
utilising the network of existing household waste recycling 
centres (HWRCs) and deploying localised collection systems. 
 
E. Why 
and 
Why 
not 
E 1-7 None E.1 No residual value is left in waste 
medicines. 
E.2 No directives or legislation exist to 
compel actors to participate RL system.  
E.4 Communication on waste medicines 
E.1 Recapture commercial value from waste medicines by 
reusing approved medicines, e.g. donating them to 
underdeveloped countries.  
E.4 Improved communications on waste medicine, at every 
level between end users and health professionals is 
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Table 7 Results of the high street survey 
Total 
respondents 
Q1. Will you 
take returned 
pills? 
Q2. Will you become 
motivated to return waste 
medicines if educated by 
GPs or pharmacists? 
Q3. Do you find it 
difficult to return waste 
medicines? 
Q4. Why did you return waste medicines to 
pharmacies 
Q5. Will you become 
motivated to return waste 
medicines if you are made 
aware of cost? 
 Y N Y N Y N Receiving 
education or direct 
communication 
from GPs or 
pharmacists 
Seeing 
posters, 
leaflets, 
etc. 
I don’t 
return 
waste 
medicines 
 
279 140 
(50%) 
139 
(50%) 
237 
(85%) 
42 (15%) 228 
(81.7%) 
51 (18.3%) 89  (31.9%) 51(18.1%) 140 (50%) 237 (85%) 
is limited, only available on government 
websites.  
E.5 waste management practices are not 
incorporated in the RL system.  
E.6 No compliance scheme is approved.  
E.7. Financial incentives are not applied.  
encouraged. 
Local councils liaise with NHS to improve communication on 
waste medicines. For example, educate residents on how to 
reduce and return medicine waste via council websites; or 
launch open events to take back and reduce medicine waste.  
E.5 PCTs (or new Clinical Commissioning Groups) 
incorporate waste management practice into community 
pharmacy contracts at three levels: reduce, reuse and properly 
dispose of.  
E.6 Set up compliance schemes.  
E.7 Apply financial incentives, i.e., sharing the cost of waste 
among all the actors by introducing charges to all prescription 
items, or enhance financial awareness by labelling medicines 
with information on full cost. 
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